- Home
- ADPT vs ADTN Comparison
ADPT vs ADTN Comparison
Compare ADPT & ADTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- ADTN
- Stock Information
- Founded
- ADPT 2009
- ADTN 1985
- Country
- ADPT United States
- ADTN United States
- Employees
- ADPT 709
- ADTN N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- ADTN Telecommunications Equipment
- Sector
- ADPT Health Care
- ADTN Telecommunications
- Exchange
- ADPT Nasdaq
- ADTN Nasdaq
- Market Cap
- ADPT 749.7M
- ADTN 639.4M
- IPO Year
- ADPT 2019
- ADTN 1994
- Fundamental
- Price
- ADPT $5.08
- ADTN $7.75
- Analyst Decision
- ADPT Buy
- ADTN Strong Buy
- Analyst Count
- ADPT 4
- ADTN 3
- Target Price
- ADPT $6.50
- ADTN $10.50
- AVG Volume (30 Days)
- ADPT 1.1M
- ADTN 689.1K
- Earning Date
- ADPT 11-07-2024
- ADTN 11-06-2024
- Dividend Yield
- ADPT N/A
- ADTN N/A
- EPS Growth
- ADPT N/A
- ADTN N/A
- EPS
- ADPT N/A
- ADTN N/A
- Revenue
- ADPT $177,282,000.00
- ADTN $905,347,000.00
- Revenue This Year
- ADPT $3.82
- ADTN N/A
- Revenue Next Year
- ADPT $20.38
- ADTN $11.07
- P/E Ratio
- ADPT N/A
- ADTN N/A
- Revenue Growth
- ADPT N/A
- ADTN N/A
- 52 Week Low
- ADPT $2.28
- ADTN $4.34
- 52 Week High
- ADPT $6.70
- ADTN $8.29
- Technical
- Relative Strength Index (RSI)
- ADPT 47.04
- ADTN 70.04
- Support Level
- ADPT $5.09
- ADTN $7.89
- Resistance Level
- ADPT $6.70
- ADTN $8.29
- Average True Range (ATR)
- ADPT 0.46
- ADTN 0.36
- MACD
- ADPT 0.00
- ADTN 0.13
- Stochastic Oscillator
- ADPT 24.48
- ADTN 76.21
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About ADTN ADTRAN Holdings Inc.
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support Segment which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions.